Nurse Practitioner Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Ellen Neylon

Clinical Nurse Specialist, Oncology Las Vegas, NV Nurse Practitioner

NPI 1174894554 CMS profile 11137607

9280 W Sunset Rd Ste 306, Las Vegas, NV 89148

Open in the dashboard

General payments

$138,413

787 records reported · program years 2021–2025

Research payments

$5,922

Paid to them · 40 records reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Ellen Neylon of Las Vegas, NV is reported in the CMS Open Payments database as having received $138,413 across 787 general payments and $5,922 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 97th percentile of Clinical Nurse Specialist, Oncology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

8 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $20,593 143
2024 General $32,086 185
2024 Research $1,440 19
2023 General $47,948 239
2023 Research $1,837 11
2022 General $20,622 122
2022 Research $2,645 10
2021 General $17,163 98

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Ellen Neylon
  • Clinical Nurse Specialist, Oncology median
  • Middle half of Clinical Nurse Specialist, Oncology
  • National median

In program year 2025, general payments to Ellen Neylon were reported at $20,593. Among 100 Clinical Nurse Specialist, Oncology profiles paid that year, the median was $250 and the middle half received between $100 and $1,290.

Show as a table
Year Ellen Neylon Clinical Nurse Specialist, Oncology median Middle half National median
2019 $0 — — $163
2020 $0 — — $114
2021 $17,163 $260 $105–$604 $132
2022 $20,622 $157 $99–$880 $149
2023 $47,948 $244 $95–$808 $160
2024 $32,086 $319 $137–$1,282 $164
2025 $20,593 $250 $100–$1,290 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Lilly USA, LLC $86,874 318 payments
  2. Novo Nordisk Inc $35,103 139 payments
  3. Eli Lilly and Company $4,846 38 payments
  4. Abbott Laboratories $2,061 79 payments
  5. Dexcom, Inc. $1,243 27 payments
  6. Corcept Therapeutics $1,062 19 payments
  7. Horizon Therapeutics plc $751 8 payments
  8. Bayer HealthCare Pharmaceuticals Inc. $442 9 payments
  9. Boehringer Ingelheim Pharmaceuticals, Inc. $412 17 payments
  10. Chiesi USA, Inc. $409 6 payments
  11. Other $5,211 127 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $83,309 109 payments
  2. Travel and Lodging $32,961 131 payments
  3. Food and Beverage $21,373 544 payments
  4. Consulting Fee $600 1 payment
  5. Education $171 2 payments
Products named General payments · program years 2021–2025
  1. MOUNJARO $64,925 228 payments
  2. RYBELSUS $31,418 103 payments
  3. Ozempic $2,816 67 payments
  4. FreeStyle Libre 3 $1,648 57 payments
  5. Dexcom G6 Transmitter $1,104 24 payments
  6. Korlym $1,062 19 payments
  7. TEPEZZA $751 8 payments
  8. Wegovy $508 9 payments
  9. Kerendia $442 9 payments
  10. FreeStyle Libre 2 $369 18 payments
  11. Other $7,326 199 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2021–2025
  1. Novo Nordisk AS $2,695 11 payments
  2. Corcept Therapeutics $1,787 10 payments
  3. AbbVie, Inc. $1,440 19 payments

Records

827 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Clinical Nurse Specialist, Oncology in Nevada

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record